# US 6,294,167 B1 · Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,294,167 B1 - Document ID: US6294167B1 - Status: Granted - Kind: B1 - Application number: 09/029,369 - Filed: 1998-11-23 - Granted: 2001-09-25 - Earliest claimed: 1995-08-25 - Assignees: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH - Inventors: Horst Lindhofer; Stefan Thierfelder - Web page: https://patentgrep.com/patent/US6294167B1 ## CPC - C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies} - C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention concerns medicaments containing antibodies which have at least one specificity and detect the MHCII antigen of a patient to be treated. The invention further concerns antibodies with two or more specificities which detect the MHCII antigen of a patient, and diagnostic compositions containing these antibodies. ## Claims ### Claim 1 A method for treating residual tumor cells in a mammalian subject comprising: transplanting bone marrow cells from a donor to said subject wherein the immunocompetent cells of said donor transplanted to said subject are characterized by an MHCII-type antigen which differs from the MHCII type antigen expressed by said tumor cells; and administering to said subject a pharmaceutically effective amount of a composition comprising an antibody which selectively binds to MHCII antigen expressed by said tumor cells, whereby as a result of said selective binding, tumor cells carrying an antibody-MHCII antigen complex are destroyed. ### Claim 2 (depends on 1) The method of claim 1, wherein said antibody is a monospecific antibody. ### Claim 3 (depends on 1) The method of claim 1, wherein said antibody possesses one or more additional non-MHCII specificities. ### Claim 4 (depends on 1) The method of claim 1, wherein said antibody has an additional specificity which recognizes an antigen on an effector cell. ### Claim 5 (depends on 4) The method of claim 4, wherein the antigen of said effector cell is selected from the group consisting of CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11b, CD13, CD16, CD28, CD32, CD33, CD40L, CD45R, CD56, CD64 and an IL-2-receptor. ### Claim 6 (depends on 4) The method of claim 4, wherein the effector cell is selected from the group consisting of T-cells, granulocytes, monocytes, macrophages, NK (natural killer) cells, mast cells and Langerhans cells. ### Claim 7 (depends on 1) The method of claim 1, wherein said antibody further possesses a specificity for binding to a second antigen expressed on a cell type selected from the group consisting of leukemic cells, hematopoietic cells, malignant cells of the epithelium, and malignant cells of the endothelium. ### Claim 8 (depends on 7) The method of claim 7, wherein said second antigen is selected from the group consisting of CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD10, CD11, CD11b, CD13, CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD30, CD33, CD37, CD40, CD41, CD44v3, CD44v6, CD45R, CD56, CD71, B220, Ig-idiotype, an IL-2-receptor, an IL-6-receptor, and a tumor-associated antigen. ### Claim 9 (depends on 1) The method of claim 1, wherein said antibody is selected from the group consisting of monoclonal, recombinant, semisynthetic, chemically modified antibodies, and antigen binding fragments thereof. ### Claim 10 (depends on 10) The method of claim 10, wherein said antibody is coupled to a moiety selected from the group consisting of an enzyme, a toxic substance, a radionuclide, biotin and a superantigen. ### Claim 11 (depends on 10) The method of claim 10, wherein said tumor cells are leukemic cells. ### Claim 12 (depends on 11) The method of claim 11, wherein said leukemic cells are selected from the group consisting of B-cell lymphoma, Hodgkin-lymphoma, anaplastic “large cell” lymphoma, adult T-cell leukemia and myeloma cells. ### Claim 13 (depends on 1) The method of claim 1, wherein the tumor cells are malignant cells of the epithelium or endothelium.